Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Internal tandem duplication (ITD) mutation in Fms-like tyrosine kinase 3 gene (FLT3/ITD) represents an unfavorable genetic change in acute myeloid leukemia (AML) and is associated with poor prognosis.

The genetics behind the progression of myelodysplasia to secondary acute myeloid leukemia (sAML) is poorly understood. In this study, we profiled somatic mutations and their dynamics using next ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Recent progress in the molecular genetics of acute myeloid leukemia (AML) has shown this disease to be more heterogeneous than previously realized. Recurrent cytogenetic and mutational changes in ...

Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...

Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

1St. Jude Children's Research Hospital, Memphis, TN.

AML: Acute myeloid leukemia; APL: Acute promyelocytic leukemia; CBF: Core-binding factor; CEBPA-DM: CCAAT enhancer-binding protein-α with double mutation; CN-AML: Cytogenetically normal AML.

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

Phenotypic and genotypic characterization of an inherited CEBPA germline mutation in a case of pediatric acute myeloid leukemia. (A) The heterozygous germline CEBPA (p.Val119Alafs*42) variant in ...